Penny Robinson, research manager, Ipsos Immunology Monitors Drug: Obinutuzumab Company: Roche Indication: Lupus Stage: Phase III Background: Obinutuzumab is a monoclonal anti-CD20 antibody (approved as Gazyva in oncology), which demonstrated positive Phase III (REGENCY) results for lupus nephritis by significantly increasing the rate of complete renal response (CRR) to 46.4% at 76 weeks compared to placebo (33.1%)
& Roth, Z
Once those stores run low, your body shifts to burning fat
Grauslund, J., Abou Taha, A., Dehghani Molander, L., Kawasaki, R., Mller, S., Hjlund, K., & Stokholm, L., Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes, International Journal of Retina and Vitreous , accepted for publication
GLP-1 is a naturally occurring incretin hormone produced by the gut and brain in response to food intake
L., & Jialal, I